Search Results

Stattic 200 mg  | 99.64%

TargetMol

Stattic is a small molecule inhibitor of STAT3. It selectively inhibits STAT3 activation, dimerization, and nuclear translocation (IC50: 5.1 μM).

More Information Supplier Page

Adezmapimod 100 mg  | 99.79%

TargetMol

Adezmapimod (PB 203580) is a p38 MAPK inhibitor (IC50: 0.3-0.5 μM). It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.

More Information Supplier Page

Adezmapimod 10 mg  | 99.79%

TargetMol

Adezmapimod (PB 203580) is a p38 MAPK inhibitor (IC50: 0.3-0.5 μM). It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.

More Information Supplier Page

Adezmapimod 200 mg  | 99.79%

TargetMol

Adezmapimod (PB 203580) is a p38 MAPK inhibitor (IC50: 0.3-0.5 μM). It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.

More Information Supplier Page

Palbociclib monohydrochloride 200 mg  | 99.73%

TargetMol

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

More Information Supplier Page

Palbociclib monohydrochloride 10 mg  | 99.73%

TargetMol

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

More Information Supplier Page

Palbociclib monohydrochloride 100 mg  | 99.73%

TargetMol

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

More Information Supplier Page

Bifendate 50 mg  | 100.00%

TargetMol

Bifendate (Bifendatatum) is commonly used to treat the transaminase elevation that caused by viral hepatitis and drug-induced liver injury.

More Information Supplier Page